Ophthalmic Drugs Market 2014-2024

3,243 views
3,136 views

Published on

For an Executive Summary of this report please contact ediz.ibrahim@visiongain.com (+44 (0)20 7549 9976) or refer to our website https://www.visiongain.com/Report/1279/Ophthalmic-Drugs-Market-Forecast-2014-2024

Published in: Business, Health & Medicine
0 Comments
2 Likes
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
3,243
On SlideShare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
94
Comments
0
Likes
2
Embeds 0
No embeds

No notes for slide

Ophthalmic Drugs Market 2014-2024

  1. 1. Ophthalmic Drugs Market Forecast 2014-2024 Prospects for Leading Companies ©notice This material is copyright by visiongain. It is against the law to reproduce any of this material without the prior written agreement of visiongain.You cannot photocopy, fax, download to database or duplicate in any other way any of the material contained in this report. Each purchase and single copy is for personal use only.
  2. 2. www.visiongain.com Contents 1. Report Overview 1.1 Global Ophthalmic Drugs Market Overview 1.2 Global Ophthalmic Drugs Market Segmentation 1.3 Why You Should Read This Report 1.4 How This Report Delivers 1.5 Key Questions Answered by This Analytical Report 1.6 Who is This Report For? 1.7 Methodology 1.8 Frequently Asked Questions (FAQ) 1.9 Associated Visiongain Reports 1.10 About Visiongain 2. Introduction to Ophthalmic Drugs 2.1 The Pharmaceutical Industry: a Very Brief Overview 2.2 The Eye: An Overview of Its Structure and Function 2.3 The Global Burden of Eye Disease 2.4 Ophthalmic Drugs: Market Segmentation 2.5 Glaucoma: the ‘Silent Thief of Sight’ 2.5.1 A Classification of Glaucoma 2.5.1.1 Primary Open-Angle Glaucoma 2.5.1.2 Acute Angle-Closure Glaucoma 2.5.1.3 Congenital Glaucoma 2.5.1.4 Secondary Glaucoma 1. Report Overview 2. Introduction to Ophthalmic Drugs
  3. 3. www.visiongain.com Contents 2.5.1.5 Normal-Tension Glaucoma 2.5.1.6 Ocular Hypertension 2.5.2 Risk Factors for Glaucoma 2.5.3 Diagnosis of Glaucoma 2.5.4 Drug Treatment of Glaucoma 2.5.5 Laser Treatment and Surgery for Glaucoma 2.6 Age-Related Macular Degeneration (AMD) 2.6.1 Dry (non-exudative) AMD 2.6.2 Wet (exudative) AMD 2.6.3 Risk Factors for AMD 2.6.4 Diagnosis of AMD 2.6.5 Treatment of AMD 2.7 Diabetic Retinopathy (DR) 2.7.1 Diagnosis of Diabetic Retinopathy 2.7.2 Treatment of Diabetic Retinopathy 2.8 Ocular Allergy and Allergic Conjunctivitis 2.8.1 Diagnosis of Ocular Allergy 2.8.2 Treatment of Ocular Allergy 2.9 Ocular Inflammatory Disease 2.9.1 Treatment of Ocular Inflammatory Disease 2.10 Eye Infections 2.10.1 Treatment of Eye Infections 2.11 Dry Eye Syndrome 2.11.1 Treatment of Dry Eye Syndrome
  4. 4. www.visiongain.com Contents 2.12 Phases of Clinical Trials 2.13 Scope of this Report 2.14 Currency Exchange Rates in This Report 3. Ophthalmic Drugs: World Market 2014-2024 3.1 The World Ophthalmic Drugs Market in 2013 3.1.1 Leading Ophthalmic Drugs 3.1.2 Leading Companies in the Ophthalmic Drugs Market 3.2 World Ophthalmic Drugs Market: Sales Forecast 2014-2024 3.3 Retinal Disorder Drugs Lead the World Ophthalmic Drugs Market 3.4 How Will Segmental Market Shares Change to 2024? 3.4.1 World Ophthalmic Drugs Market: Drivers and Restraints 2014-2024 4. Leading National Markets 2014-2024 4.1 Geographical Breakdown of the World Ophthalmic Drugs Market 4.2 World Ophthalmic Drugs Market: National Markets Forecast 2014-2024 4.2.1 How Will National Market Shares Change to 2024? 4.3 The US Ophthalmic Drugs Market 2014-2024 4.3.1 US Ophthalmic Drugs Market Forecast 2014-2024 4.3.2 US Ophthalmic Drugs Market: Trends and Developments 4.3.2.1 Affordable Care Act: Expanding Medicare Coverage 4.3.2.2 A US Biosimilars Market? 4.4 Japanese Ophthalmic Drugs Market 2014-2024 3. Ophthalmic Drugs: World Market 2014-2024 4. Leading National Markets 2014-2024
  5. 5. www.visiongain.com Contents 4.4.1 Japanese Ophthalmic Drugs Market Forecast 2014-2024 4.4.2 Japanese Ophthalmic Drugs Market: Trends and Developments 4.4.2.1 The Cost of Treatment in Japan 4.5 Chinese Ophthalmic Drugs Market 2014-2024 4.5.1 Chinese Ophthalmic Drugs Market Forecast 2014-2024 4.5.2 Chinese Ophthalmic Drugs Market: Trends and Developments 4.5.2.1 Expansion of Healthcare Coverage and Reimbursement 4.5.2.2 Price Controls and the Anhui Model 4.6 EU5 Ophthalmic Drugs Market 2014-2024 4.6.1 German Ophthalmic Drugs Market Forecast 2014-2024 4.6.2 French Ophthalmic Drugs Market Forecast 2014-2024 4.6.3 UK Ophthalmic Drugs Market Forecast 2014-2024 4.6.4 Italian Ophthalmic Drugs Market Forecast 2014-2024 4.6.5 Spanish Ophthalmic Drugs Market Forecast 2014-2024 4.7 Brazilian Ophthalmic Drugs Market 2014-2024 4.7.1 Brazilian Ophthalmic Drugs Market Forecast 2014-2024 4.7.2 Brazilian Ophthalmic Drugs Market: Trends and Developments 4.7.2.1 Increasing Access to Medicines 4.8 Russian Ophthalmic Drugs Market 2014-2024 4.8.1 Russian Ophthalmic Drugs Market Forecast 2014-2024 4.8.2 Russian Ophthalmic Drugs Market: Trends and Developments 4.8.2.1 Pharma2020, Healthcare and Industry Reform 4.9 Indian Ophthalmic Drugs Market 2014-2024 4.9.1 Indian Ophthalmic Drugs Market Forecast 2014-2024
  6. 6. www.visiongain.com Contents 4.9.2 Indian Ophthalmic Drugs Market: Trends and Developments 4.9.2.1 Drug Prices Control Order 2013 4.9.2.2 Expansion of Healthcare Provision 4.10 Mexican Ophthalmic Drugs Market 2014-2024 4.10.1 Mexican Ophthalmic Drugs Market Forecast 2014-2024 4.10.2 Mexican Ophthalmic Drugs Market: Trends and Developments 4.10.2.1 Lupin Acquires Laboratorios Grin, Entering the Mexican Market 4.10.2.2 Seguro Popular: Mexican Healthcare Reform 4.10.2.3 International Interest in Mexico 5. Retinal Disorder Drugs Market 2014-2024 5.1 Retinal Disorder Drugs: the Rise of Anti-VEGF Therapy 5.2 Leading Retinal Disorder Drugs in 2013 5.3 Retinal Disorder Drugs: Market Forecast 2014-2024 5.4 Market Share of Leading Retinal Disorder Drugs to 2024 5.5 Retinal Disorder Drugs: Trends and Developments 5.5.1 Lucentis Dominates the Retinal Disorder Drugs Market 5.5.2 Roche and Novartis Fined Over Lucentis-Avastin Collusion 5.5.3 Requiring Avastin Use in AMD? 5.5.4 Novartis Licenses Ophthotech’s Fovista 5.5.5 Jetrea Launch Disappoints Analysts 5.5.6 Conbercept Approved in China 5.5.7 Drug/Device Combination Products Entering the Market 5.5.8 Advances in Regenerative Medicine 5. Retinal Disorder Drugs Market 2014-2024
  7. 7. www.visiongain.com Contents 5.6 Lucentis (ranibizumab, Roche/Novartis) 5.6.1 Lucentis: Sales Forecast 2014-2024 5.6.2 Less Frequent Dosing Approved in US 5.6.3 New Indications for Lucentis 5.6.4 Lucentis/Fovista Combination Therapy? 5.7 Eylea (aflibercept, Regeneron/Bayer/Santen) 5.7.1 Eylea: Sales Forecast 2014-2024 5.7.2 The Comparative Efficacy of Eylea 5.7.3 Combination Therapy with Eylea and a PDGFR-beta Inhibitor 5.8 Avastin (bevacizumab, Roche) 5.8.1 Avastin: Sales Forecast 2014-2024 5.8.2 Compounding Pharmacies and Safety Risks 5.9 Visudyne (verteporfin, Valeant/Novartis) 5.9.1 Visudyne: Sales Forecast 2014-2024 5.10 Jetrea (ocriplasmin, ThromboGenics/Novartis) 5.10.1 Jetrea: Sales Forecast 2014-2024 5.10.2 Potential Acquisition of ThromboGenics? 5.10.3 R&D Agreements with Eleven Biotherapeutics and Bicycle Therapeutics 5.11 Other Retinal Disorder Drugs 5.11.1 Iluvien (fluocinolone implant, Alimera Sciences) 5.11.2 Ozurdex (dexamethasone implant, Allergan) 6. Allergic, Inflammatory and Infective Drugs Market 2014-2024 6.1 Allergic, Inflammatory and Infective Drugs: Introduction 6. Allergic, Inflammatory and Infective Drugs Market 2014-2024
  8. 8. www.visiongain.com Contents 6.2 Allergic, Inflammatory and Infective Drugs: Submarket Breakdown 6.3 Leading Allergic, Inflammatory and Infective Drugs in 2013 6.4 Allergic, Inflammatory and Infective Drugs: Market Forecast 2014-2024 6.5 Market Share of Leading Allergic, Inflammatory and Infective Drugs to 2024 6.6 Allergic, Inflammatory and Infective Drugs: Trends and Developments 6.6.1 Growth Prospects in 2014-2024 6.6.2Lupin Launches Generic Zymaxid 6.6.3 New Topical NSAIDs Launched: Prolensa and Ilevro 6.7 Patanol and Pataday (olopatadine, Alcon) 6.7.1 Patanol: Sales Forecast 2014-2024 6.7.2 Pataday: Sales Forecast 2014-2024 6.7.3 Generic Competition for Patanol/Pataday? 6.8 Vigamox (moxifloxacin, Alcon) 6.8.1 Vigamox: Sales Forecast 2014-2024 6.8.2 Generic Challenges to Vigamox 6.8.3 Moxeza: A Next-Generation Form of Vigamox 6.9 TobraDex (tobramycin/dexamethasone, Alcon) 6.9.1 TobraDex: Sales Forecast 2014-2024 6.9.2 TobraDex ST (Alcon/Novartis) 6.10 Bromday (bromfenac, Valeant) 6.10.1 Bromday: Sales Forecast 2014-2024 6.10.2 Prolensa: A New Formulation of Bromfenac 6.10.3 Competition from Ilevro/Nevanac 6.11 Cravit (levofloxacin, Santen)
  9. 9. www.visiongain.com Contents 6.11.1 Cravit: Sales Forecast 2014-2024 6.12 Acular (ketorolac, Allergan) 6.12.1 Acular: Sales Forecast 2014-2024 6.13 AzaSite (azithromycin, Akorn) 6.13.1 AzaSite: Sales Forecast 2014-2024 7. Glaucoma Drugs Market 2014-2024 7.1 Glaucoma: Prostaglandin Analogues Lead the Market 7.2 Leading Glaucoma Drugs in 2013 7.3 Glaucoma Drugs: Market Forecast 2014-2024 7.4 Market Share of Leading Glaucoma Drugs to 2024 7.5 Glaucoma Drugs: Trends and Developments 7.5.1 Revenues Threatened by Patent Expiration 7.5.2 Preservative-Free Formulation Trends 7.5.3 Innovation in Treatments for Glaucoma 7.5.4 Simbrinza Launched as First Beta-Blocker-Free Combination 7.6 Lumigan and Ganfort (bimatoprost, Allergan) 7.6.1 Lumigan and Ganfort: Sales Forecast 2014-2024 7.7 Xalatan and Xalacom (latanoprost, Pfizer) 7.7.1 Xalatan/Xalacom: Sales Forecast 2014-2024 7.8 Travatan/Travatan Z and DuoTrav (travoprost, Novartis) 7.8.1 Travatan/Travatan Z and DuoTrav: Sales Forecast 2014-2024 7.9 Alphagan/Alphagan P and Combigan (brimonidine, Allergan) 7.9.1 Alphagan/Alphagan P and Combigan: Sales Forecast 2014-2024 7. Glaucoma Drugs Market 2014-2024
  10. 10. www.visiongain.com Contents 7.10 Trusopt and Cosopt/Cosopt PF (dorzolamide, Merck) 7.10.1 Trusopt: Sales Forecast 2014-2024 7.10.2 Cosopt and Cosopt PF: Sales Forecast 2014-2024 7.11 Azopt (brinzolamide, Novartis) 7.11.1 Azopt: Sales Forecast 2014-2024 7.12 Tapros (tafluprost, Santen) 7.12.1 Tapros/Taflotan: Sales Forecast 2014-2024 7.13 Zioptan (tafluprost, Akorn) 7.13.1 Zioptan: Sales Forecast 2014-2024 8. Dry Eye Drugs Market 2014-2024 8.1 Dry Eye: Introduction 8.2 Leading Dry Eye Drugs in 2013 8.3 Dry Eye Drugs: Market Forecast 2014-2024 8.4 Market Share of Leading Dry Eye Drugs to 2024 8.5 Dry Eye Drugs: Trends and Developments 8.5.1 Will Generic Restasis Launch in 2014? 8.5.2 Intensive Research Focus on Dry Eye 8.5.3 Improving Diagnostic Tools 8.6 Restasis (ciclosporin, Allergan) 8.6.1 Restasis: Sales Forecast 2014-2024 8.7 Refresh Brand Products (Allergan) 8.7.1 Refresh Brand Products: Sales Forecast 2014-2024 8.8 Hyalein (hyaluronic acid, Santen) 8. Dry Eye Drugs Market 2014-2024
  11. 11. www.visiongain.com Contents 8.8.1 Hyalein: Sales Forecast 2014-2024 8.9 Diquas (diaquafosol, Santen) 8.9.1 Diquas: Sales Forecast 2014-2024 8.10 Other Ophthalmic Drugs 8.10.1 Hetlioz (tasimelteon, Vanda Pharmaceuticals) 8.10.2 Hetlioz: Sales Forecast 2014-2024 9. Leading Companies in the Ophthalmic Drugs Market 9.1 Novartis (Alcon) 9.1.1 Novartis: Ophthalmic Drugs Portfolio 9.1.2 Novartis: Sales Forecast 2014-2024 9.1.3 Novartis: Products in Development 9.1.4 Novartis: Recent Developments 9.1.4.1 Novartis Restructures Following Strategic Review 9.1.4.2 Novartis Licenses Ophthothech’s Fovista 9.2 Allergan 9.2.1 Allergan: Ophthalmic Drugs Portfolio 9.2.2 Allergan: Sales Forecast 2014-2024 9.2.3 Allergan: Products in Development 9.2.3.1 Novadur (Intravitreal Brimonidine Implant) 9.2.4 Allergan: Recent Developments 9.2.4.1 Ozurdex (Dexamethasone Intravitreal Implant): The First Drug Therapy for Diabetic Macular Oedema 9.2.4.2 Prospects for Generic Restasis? 9. Leading Companies in the Ophthalmic Drugs Market
  12. 12. www.visiongain.com Contents 9.2.4.3 Allergan Rejects Valeant Bid 9.2.4.4 Allergan Considering Acquiring Shire? 9.3 Roche 9.3.1 Roche: Ophthalmic Drugs Portfolio 9.3.1.1 Lucentis: US Sales Forecast 2014-2024 9.3.2 Roche: Sales Forecast 2014-2024 9.3.3 Roche: Products in Development 9.4 Valeant 9.4.1 Valeant: Ophthalmic Drugs Portfolio 9.4.2 Valeant: Sales Forecast 2014-2024 9.4.3 Valeant: Products in Development 9.4.4 Valeant: Recent Developments 9.4.4.1 Valeant’s Acquisition of Bausch and Lomb: Aggressive Expansion? 9.4.4.2 Bausch and Lomb Had Acquired ISTA Pharmaceuticals 9.5 Regeneron 9.5.1 Regeneron: Ophthalmic Drugs Portfolio 9.5.2 Regeneron: Sales Forecast 2014-2024 9.5.3 Regeneron: Products in Development 9.5.4 Regeneron: Recent Developments 9.5.4.1 FDA Approves Zaltrap (aflibercept) 9.5.4.2 Eylea/Zaltrap and the Davis-Smyth Patent Agreements 9.6 Santen 9.6.1 Santen: Ophthalmic Drugs Portfolio 9.6.2 Santen: Sales Forecast 2014-2024
  13. 13. www.visiongain.com Contents 9.6.3 Santen: Products in Development 9.6.4 Santen: Recent Developments 9.6.4.1 Santen Acquires Novagali Pharma 9.6.4.2 Santen Launches Alesion in Japan 9.6.4.3 Santen Acquires Merck’s Ophthalmic Drugs Portfolio 9.7 Pfizer 9.7.1 Pfizer: Ophthalmic Drugs Portfolio 9.7.1.1 Macugen (Valeant/Pfizer) 9.7.2 Pfizer: Sales Forecast 2014-2024 9.7.3 Pfizer: Products in Development 9.7.4 Pfizer: Recent Developments 9.7.4.1 Pfizer Attempts to Acquire AstraZeneca 9.8 Merck 9.8.1 Merck: Ophthalmic Drugs Portfolio 9.8.2 Merck: Sales Forecast 2014-2024 9.8.3 Merck: Products in Development 9.9 Bayer 9.9.1 Bayer: Ophthalmic Drugs Portfolio 9.9.2 Bayer: Sales Forecast 2014-2024 9.10 Senju 9.10.1 Senju: Ophthalmic Drugs Portfolio 9.10.2 Senju: Sales Forecast 2014-2024 9.10.3 Senju: Products in Development 9.10.3.1 Y-39983 (SNJ-1656)
  14. 14. www.visiongain.com Contents 9.10.3.2 Difluprednate (SJE-2079) 10. Ophthalmic Drugs Pipeline Analysis 2014-2024 10.1 The Ophthalmic Drugs Pipeline: Richest in Retinal Disorder Agents 10.2 The Retinal Disorders Pipeline 10.2.1 Will Bevasiranib (RXi Pharmaceuticals) Resume Development? 10.3 Retinal Disorders: Filed or Recently Launched 10.3.1 Compaq Sipp (conbercept, Chengdu Kanghong Pharmaceutical) 10.3.2 Lipidil (fenofibrate, Abbott) 10.3.3 Iluvien (fluocinolone, Alimera) 10.4 Retinal Disorders: Phase 3 Pipeline 10.4.1 Fovista and Zimura (Ophthotech) 10.4.2 MC-1101 (hydralazine, MacuCLEAR) 10.4.3 Tandospirone (serotonin 1A agonist, Alcon) 10.4.4 UF-021 (unoprostone, R-Tech Ueno) 10.5 Retinal Disorders: Phase 2 Pipeline 10.5.1 AKB-9778 (Tie2 activator, Aerpio Therapeutics) 10.5.2 ALG-1001 (Integrin peptide therapy, Allegro/Senju) 10.5.3 AGN150998 and MP0260 (Anti-VEGF DARPins, Allergan) 10.5.4 AGN208397 (beclomethasone, Allergan) 10.5.5 CPC-551 (Colby Pharmaceutical) 10.5.6 Darapladib and GSK933776 (GSK) 10.5.7 ESBA1008 (anti-VEGF mAb, Alcon) 10.5.8 iCo-007 (antisense inhibitor of C-raf kinase mRNA, iCo Therapeutics) 10. Ophthalmic Drugs Pipeline Analysis 2014-2024
  15. 15. www.visiongain.com Contents 10.5.9 iSONEP (sonepcizumab, Lpath) 10.5.10 Lampalizumab (anti-Factor D Fab, Roche) 10.5.11 LFG316 (anti-C5 mAb, Novartis) 10.5.12 Novadur (Intravitreal brimonidine implant, Allergan) 10.5.13 Optina (danazol, Ampio Pharmaceuticals) 10.5.14 PF-655 (synthetic siRNA, Quark/Pfizer) 10.5.15 Premiplex (protein replacement therapy, Shire) 10.5.16 Renexus (ciliary neurotrophic factor, Neurotech) 10.5.17 Squalamine (anti-angiogenic drug, OHR Pharmaceutical) 10.5.18 Zybrestat (fosbretabulin, Oxigene/Symphony VIDA) 10.6 Retinal Disorders: Phase 1 and Preclinical Pipeline 10.6.1 BDM-E (BioDiem) 10.6.2 NADPH Oxidase Inhibitors (Alimera) 10.6.3 NS2 (aldehyde trap, Aldeyra Therapeutics) 10.6.4 PAN-90806 (topical VEGF inhibitor, PanOptica) 10.6.5 Plasma Kallikrein Inhibitors (KalVista) 10.6.6 QLT091001 (synthetic retinoid, QLT) 10.7 Allergic, Inflammatory and Infective Drugs: Phase 3 Pipeline 10.7.1 EGP-437 (dexamethasone, EyeGate) 10.7.2 IBI-10090 and IBI-20089 (Icon Bioscience) 10.7.3 LE-MPP (loteprednol etabonate, Kala) 10.8 Allergic, Inflammatory and Infective Drugs: Phase 2 Pipeline 10.8.1 CF101 (adenosine A3 receptor agonist, Can-Fite BioPharma and OphthaliX) 10.8.2 FST-100 (povidone-iodine/dexamethasone, ForeSight Biotherapeutics)
  16. 16. www.visiongain.com Contents 10.8.3 NVC-422 (auriclosene, NovaBay) 10.8.4 Sarilumab (Regeneron) 10.8.5 V404 PDS (ForSight VISION4) 10.9 Allergic, Inflammatory and Infective Drugs: Phase 1 and Preclinical Pipeline 10.9.1 Finafloxacin (MerLion Pharmaceuticals/Novartis) 10.10 Glaucoma: Phase 2 and Phase 3 Pipeline 10.10.1 Latanoprostene Bunod (BOL-303259-X, Valeant) 10.10.2 AMA0076 (ROCK inhibitor, Amakem) 10.10.3 Rhopressa (AR-13324; ROCK and NET inhibitor) and Roclatan (PG324; ROCK inhibitor), Aerie Pharmaceuticals 10.11 Glaucoma: Phase 1 and Preclinical Pipeline 10.12 Dry Eye: Phase 3 Pipeline 10.12.1 EBI-005 (IL-1R antagonist, Eleven Biotherapeutics) 10.12.2 Lifitegrast (integrin antagonist, Shire) 10.12.3 MIM-D3 (tyrosine kinase receptor antagonist, Valeant) 10.12.4 SI-614 (modified hyaluronate, Seikagaku) 10.13 Dry Eye: Phase 2 Pipeline 10.13.1 ESBA105 (TNF-alpha antibody, Novartis/Alcon) 10.13.2 Kineret (anakinra: IL-1 receptor antagonist, Amgen/Sobi) 10.14 Other Ophthalmic Drugs Pipeline 10.14.1 Brimonidine for Eye Whitening (Valeant) 10.14.2 GS-101 (aganirsen, Gene Signal) 10.14.3 Omidria (phenylephrine/ketorolac, Omeros)
  17. 17. www.visiongain.com Contents 11. Qualitative Analysis of the Ophthalmic Drugs Market 2014-2024 11.1 SWOT Analysis of the Ophthalmic Drugs Market 11.2 Strengths 11.2.1 Advances in Drug Delivery Technologies 11.2.2 Support for Reimbursement 11.2.3 Strong R&D Pipeline 11.2.3.1 Gene Therapy and RNA Interference Technology 11.2.3.2 New Ophthalmic Therapeutic Applications for Drugs 11.2.3.3 Development of Neuroprotective Anti-Glaucoma Medications 11.2.3.4 Working with Biomarkers 11.3 Weaknesses 11.3.1 Patient Adherence to Treatment 11.3.2 High Treatment Burden 11.3.3 Under-Diagnosis and Under-Treatment 11.4 Opportunities 11.4.1 Increasing Disease Prevalence 11.4.1.1 Ageing of the World Population 11.4.1.2 Increasing Prevalence of Eye Diseases and Diabetes 11.4.1.3 Glaucoma and Retinal Disorders Will Have the Most-Marked Increases in Prevalence 11.4.2 Unmet Clinical Need in Many Disease Areas 11.4.3 Higher Growth in Emerging Markets 11.4.4 Sustained-Release Ocular Implants 11.5 Threats 11. Qualitative Analysis of the Ophthalmic Drugs Market 2014-2024
  18. 18. www.visiongain.com Contents 11.5.1 Generic Competition 11.5.2 Price Regulation 11.5.3 Biosimilars 11.5.4 Increasing R&D Costs 11.6 Porter’s Five Forces Analysis of the Ophthalmic Drugs Market 11.6.1 Rivalry Among Competitors [Medium] 11.6.2 Threat of New Entrants [Low] 11.6.3 Power of Suppliers [Low] 11.6.4 Power of Buyers [Medium] 11.6.5 Threat of Substitutes [Medium] 12. Research Interviews 12.1 Interview with Cathy Yelf, Head of External Relations, Macular Society, Andover, Hampshire, UK 12.1.1 The Work of the Macular Society 12.1.2 Developments in Treating AMD 12.1.3 Lucentis, Eylea and Avastin 12.1.4 Developments in Diagnosis of Eye Conditions 12.1.5 Unmet Needs in AMD 12.1.6 The Future of the Ophthalmic Drugs Market? 12.2 Interview with the Royal National Institute of Blind People (RNIB), London, UK 12.2.1 The Work of RNIB 12.2.2 Developments in Ophthalmology 12.2.3 Unmet Needs in Glaucoma and AMD 12. Research Interviews
  19. 19. www.visiongain.com Contents 12.2.4 The Future of the Ophthalmic Drugs Market? 12.3 Interview with Dr Charles Wykoff, Retina Consultants of Houston, Texas, US 12.3.1 Developments in Ophthalmology 12.3.2 Unmet Needs in Ophthalmology 12.3.3 Regulatory Issues in the US Market 12.3.4 The Future of the Ophthalmic Drugs Market? 12.4 Interview with Professor Manju Subramanian, Associate Professor, Department of Ophthalmology, Boston University School of Medicine, Boston, Massachusetts, US 12.4.1 Developments in Ophthalmology 12.4.2 Unmet Needs in Ophthalmology 12.4.3 Treatments for Glaucoma, AMD and Dry Eye 12.4.4 Lucentis, Eylea and Avastin 12.4.5 Jetrea for Retinal Disorders 12.4.6 The Future of the Ophthalmic Drugs Market? 12.5 Interview with a Spokesperson for Vanda Pharmaceuticals, Washington DC, US 12.5.1 Commercialising Hetlioz 12.5.2 Future Prospects for Vanda 12.6 Interview with Professor David T. Shima, PhD, Institute of Ophthalmology, University College London, UK 12.6.1 On the Role of VEGF in Retinal Disorders 12.6.2 On Candidate Molecule E10030 12.6.3 On Candidate Molecule JSM 6427 12.6.4 On New Sustained Release Formulations 12.6.5 On Delta-Notch Signalling 12.6.6 Potential Clinical Crossovers Between Ophthalmology and Oncology
  20. 20. www.visiongain.com Contents 12.6.7 Commercial and Clinical Possibilities in the Ophthalmology Market 12.6.8 On the Possibilities of Research into the Endothelial Fenestra 12.7 Expert Interview 7: Authority from a Company in the Industry (Views Provided Anonymously) 12.7.1 Key Unmet Needs 12.7.2 Challenges Facing the Ophthalmic Sector 12.7.3 On Current Ophthalmic Treatments and Their Effectiveness 12.7.4 On Opportunities in the Ophthalmic Sector 12.8 Interview with Sean Ainsworth, CEO and Founder of RetroSense Therapeutics, Ann Arbor, Michigan, USA 12.8.1 The Optogenetic Approach to Vision Restoration 12.8.2 Choosing Disease Targets and Delivery Vectors 12.8.3 The Regulatory Picture 12.8.4 Gene Therapies in AMD and Other Ophthalmic Therapeutic Areas 12.8.5 The Next Ten Years for Gene Therapy 12.9 Interview with Philip G. Ralston, Jr., CEO of MacuCLEAR, Plano, Texas, USA 12.9.1 MC-1101: Identifying and Treating Chiou Syndrome 12.9.2 Preventing Dry AMD Progression 12.9.3 Treating the Root Cause of Dry AMD 12.9.4 Phase 3: Endpoints and Prospects for MC-1101 12.10 Interview with Dr Michael Stewart, Associate Professor, Mayo Clinic, Jacksonville, Florida, USA 12.10.1 The Impact of Eylea 12.10.2 The Comparative Dosing Schedules of Eylea and Lucentis 12.10.3 Patient Transitioning to Eylea: Salvage Switching
  21. 21. www.visiongain.com Contents 12.10.4 Avastin after the CATT Study 12.10.5 Prospects for Eylea in Other Indications and Combinations 12.10.6 Future Possibilities in Wet AMD Treatment 13. Conclusions 13.1 Ophthalmic Pharmaceuticals: A Growing Niche Market 13.2 The World Ophthalmic Drugs Market in 2013 13.2.1 Current Leading Ophthalmic Drugs Segments 13.2.2 Leading Ophthalmic Drugs Products 13.2.3 Leading Ophthalmic Drugs Companies 13.2.4 Leading National Markets 13.3 World Ophthalmic Drugs Market Forecast 2014-2024 13.4 Ophthalmic Drugs Late-Stage Pipeline 13.5 The Future of the Ophthalmic Drugs Market? 13.5.1 Increasing Revenue Concentration among Specialist Companies 13.5.2 The Rise of Generics 13.5.3 Small Companies Can Have a Big Impact 13.5.4 What Will Succeed in the Ophthalmic Drugs Market? 13. Conclusions
  22. 22. www.visiongain.com Page 101 Ophthalmic Drugs Market Forecast 2014-2024: Prospects for Leading Companies highest in Europe, a trend that will contribute to slowing pharmaceutical sales growth. The tendering system and other cost-cutting measures will also restrain growth. 4.6.2 French Ophthalmic Drugs Market Forecast 2014-2024 Visiongain estimates that in 2013, the French ophthalmic drugs market reached $724m, representing 3.7% of the world market. In 2014 the French market will increase to $742m, up 2.5% on 2013. Table 4.9 and Figure 4.11 show visiongain’s forecast for the French ophthalmic drugs market over 2013-2024. Table 4.9 French Ophthalmic Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2013-2024 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 France ($m) 724 742 760 780 795 814 831 850 868 888 912 943 Annual Growth Rate (%) 2.5 2.4 2.6 1.9 2.4 2.0 2.3 2.2 2.3 2.7 3.3 CAGR (%, 2013-2018 and 2018-2024) 2.4 2.5 CAGR (%, 2013-2024) 2.4 Figure 4.11 French Ophthalmic Drugs Market Forecast: Revenues ($m), AGR (%), 2013-2024 0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 0 100 200 300 400 500 600 700 800 900 1,000 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 AGR(%) Sales($m) Year Sales ($m) AGR (%) Source: visiongain 2014 Source: visiongain 2014
  23. 23. www.visiongain.com Page 192 Ophthalmic Drugs Market Forecast 2014-2024: Prospects for Leading Companies revenues will reach $238m in 2024, representing a CAGR of 6.1% over 2018-2024 and an overall CAGR of 11.1% over 2013-2024. Table 8.7 and Figure 8.8 show visiongain’s estimates of Diquas revenues over 2013-2024. Table 8.7 Santen: Diquas Revenue ($m), AGR (%), CAGR (%), 2013-2024 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 Diquas ($m) 75 97 117 134 150 167 181 196 208 219 228 238 Annual Growth Rate (%) 30.0 20.0 15.0 12.0 11.1 8.5 8.0 6.5 5.2 4.2 4.0 CAGR (%, 2013-2018 and 2018-2024) 17.4 6.1 CAGR (%, 2013-2024) 11.1 Figure 8.8 Santen: Diquas Revenue ($m), AGR (%), 2013-2024 8.10 Other Ophthalmic Drugs 8.10.1 Hetlioz (tasimelteon, Vanda Pharmaceuticals) Vanda Pharmaceuticals is a biopharmaceutical company based in Washington, DC. It focuses on developing drugs for treating CNS disorders, such as its other available drug Fanapt (iloperidone) for schizophrenia. Hetlioz (tasimelteon) is an oral drug for the treatment of non-24-hour disorder, a 0.0 5.0 10.0 15.0 20.0 25.0 30.0 35.0 0 50 100 150 200 250 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 AGR(%) Sales($m) Year Sales ($m) AGR (%) Source: visiongain 2014 Source: visiongain 2014
  24. 24. www.visiongain.com Page 224 Ophthalmic Drugs Market Forecast 2014-2024: Prospects for Leading Companies 9.7.2 Pfizer: Sales Forecast 2014-2024 Table 9.15 and Figure 9.8 show visiongain’s estimates of Pfizer’s ophthalmic drug revenues over 2013-2024. Table 9.15 Pfizer: Ophthalmic Drugs Revenue ($m), AGR (%), CAGR (%), 2013-2024 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 Pfizer ($m) 595 469 399 281 240 228 226 231 237 244 251 259 Annual Growth Rate (%) -21.2 -14.8 -29.5 -14.7 -4.9 -1.0 1.9 2.9 2.9 2.9 2.9 CAGR (%, 2013-2018 and 2018-2024) -17.4 2.1 CAGR (%, 2013-2024) -7.3 Figure 9.8 Pfizer: Ophthalmic Drugs Revenue ($m), AGR (%), 2013-2024 Pfizer’s ophthalmic drug revenues peaked in 2010, reaching an estimated $1,758m largely due to sales of Xalatan and Xalacom. However, revenues have since fallen to reach $595m in 2013, a CAGR of -30.3% over 2010-2013 mirroring the decline in revenues from Xalatan/Xalacom. This decline was primarily due to generic competition for Xalatan/Xalacom, which lost patent protection in all major pharmaceutical markets. Xalatan lost exclusivity in the US in March 2011 and Pfizer further lost exclusivity for Xalatan and Xalacom in 15 major European markets in January 2012. -35.0 -30.0 -25.0 -20.0 -15.0 -10.0 -5.0 0.0 5.0 0 100 200 300 400 500 600 700 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 AGR(%) Sales($m) Year Sales ($m) AGR (%) Source: visiongain 2014 Source: visiongain 2014

×